T. Rowe Price Associates, Inc. 13D and 13G filings for Crinetics Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 10:07 am Purchase | 2026-03-31 | 13G | CRINETICS PHARMACEUTICALS INC CRNX | T. Rowe Price Associates, Inc. | 5,355,011 5.100% | 410,254 (+8.30%) | Filing |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | CRINETICS PHARMACEUTICALS INC CRNX | T. Rowe Price Associates, Inc. | 4,944,757 6.200% | 4,944,757 (New Position) | Filing |